CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
Inggenol Mebutate 0.015%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02446223
NCT02446223Phase 4Completed
CompareCT.gov

A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015%

Goldman, Butterwick, Fitzpatrick and Groff·interventional·Posted May 18, 2015·Updated Sep 6, 2019

In Brief

A Phase 4 clinical trial evaluating Inggenol Mebutate 0.015% for Actinic Keratosis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
CollaboratorsLEO Pharma

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 18, 2015
Enrollment StartJan 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.1 years ago

Interventions

Inggenol Mebutate 0.015%drug